Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib

• Main Authors: Chai, Chee Shee, Lin, O. Po, Liam, Chong Kin, Pang, Yong Kek, Ho, G. F., Alip, A., Wong, Chee Kuan, Poh, Mau Ern, Tan, Jiunn Liang
• Format: E-Article
• Language: English
• Published: Oxford university press 2019
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://ir.unimas.my/id/eprint/28062/1/ESMO%202019%202.pdf; http://ir.unimas.my/id/eprint/28062/; https://doi.org/10.1093/annonc/mdz437.020
• Institution: Universiti Malaysia Sarawak

Abstract Background Patients receiving first-line afatinib, gefitinib or erlotinib for epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer develop progression of disease (PD) after an average of 9-13 months. Methods A retrospective analysis of PD pattern and prev...